<div id="readability-page-1">・The agreement carries a potential value of up to $100 million, but Jupiter will make an upfront payment of $3.3 million. ・ALA-002 is a patented MDMA formulation recognized by the U.S. Food and Drug Administration as a novel chemical entity. ・JUNS stock is set to test a key technical milestone for the first time in nearly seven months. Shares of Ju...</div>

JUNS

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

<p>Jupiter Neurosciences, Inc. (JUNS) 在近一年来经历了最大单日涨幅，股价上涨超过 50%，原因是获得了一项价值 1 亿美元的 MDMA 基础药物 ALA-002 的许可协议。该协议包括 330 万美元的预付款，并使 JUNS 能够在不断增长的迷幻疗法市场中获利。零售投资者的情绪变得极为乐观，预计股价将达到 1 美元，尽管今年股价已下跌 60%</p>

JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1

Jupiter Neurosciences

JUNS 股票因 1 亿美元的 MDMA 药物许可协议而创下近一年内的单日最大涨幅，零售投资者预计股价将升至 1 美元